ReviewCells2019
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Integrating Proteomics and Predictive Model: Elucidating the Role of Aminated Nanodiamonds in Suppressing Prostate Cancer Growth.ACS omega · 2026Article
- Hsa_circ_0030568 Promotes the Proliferation and Migration of Prostate Cancer CellsCombinatorial chemistry & high throughput screening · 2026Article
- The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.Cell death & disease · 2024Review
- Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.Current oncology reports · 2024Review
- Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy.Biomedicines · 2023Review
- Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.International journal of molecular sciences · 2022Review
- PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.Biomedicines · 2022Review
- The functional roles of the circRNA/Wnt axis in cancer.Molecular cancer · 2022Review
- MIRO2 Regulates Prostate Cancer Cell Growth via GCN1-Dependent Stress Signaling.Molecular cancer research : MCR · 2022Article
- Review
- A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer.Frontiers in endocrinology · 2022Article
- Molecular Mechanisms of Coffee on Prostate Cancer Prevention.BioMed research international · 2022Review
- Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer.Frontiers in immunology · 2022Article
- An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.International journal of molecular sciences · 2021Review
- Increase inInternational journal of molecular sciences · 2021Article
- Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.Cancers · 2021Article
- Review
- Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.Translational andrology and urology · 2021Review
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak.Viruses · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients' clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.